G1 Therapeutics to Present at August Investor Conferences
August 05, 2015 08:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Aug. 5, 2015 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that senior management will be presenting at two investor...
G1 Therapeutics to Present at the BIO International Convention
June 10, 2015 09:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., June 10, 2015 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that Chief Business Officer Greg Mossinghoff will present a...
G1 Therapeutics Announces Positive Phase 1a Data for CDK4/6 Inhibitor G1T28
May 27, 2015 09:00 ET
|
G1 Therapeutics
G1T28 produced robust, transient, G1 cell cycle arrest of bone marrow cells
Compound was well tolerated with predictable pharmacokinetic / pharmacodynamic activity
Data support...
G1 Therapeutics to Present New Data on CDK4/6 Inhibitor G1T28 at the 2015 American Society of Clinical Oncology Annual Meeting
May 13, 2015 17:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., May 13, 2015 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage pharmaceutical company developing small-molecule therapies to address significant unmet needs in...
G1 Therapeutics to Present New Data on CDK4/6 Inhibitor G1T28 at the American Association for Cancer Research Annual Meeting
April 15, 2015 09:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., April 15, 2015 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage pharmaceutical company developing small-molecule therapies to address significant unmet needs...
G1 Therapeutics to Present at the 14th Annual Needham Healthcare Conference
April 08, 2015 09:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., April 8, 2015 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage pharmaceutical company developing small-molecule therapies to address significant unmet needs in...
G1 Therapeutics to Present at 22nd Annual Future Leaders in the Biotech Industry Conference
March 16, 2015 09:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., March 16, 2015 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage pharmaceutical company developing small-molecule therapies to address significant unmet needs...
G1 Therapeutics Raises $33 Million in Series B Financing
February 05, 2015 07:30 ET
|
G1 Therapeutics
Proceeds to accelerate clinical development of lead CDK4/6 inhibitor for antineoplastic and chemoprotection indications
Fred Eshelman and Peter Kolchinsky join board of...
G1 Therapeutics to Present at 17th Annual BIO CEO & Investor Conference
February 02, 2015 09:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Feb. 2, 2015 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage pharmaceutical company developing small-molecule therapies to address significant unmet needs in...
G1 Therapeutics Initiates Phase 1 Clinical Trial of G1T28-1
September 10, 2014 13:00 ET
|
G1 Therapeutics
Lead drug candidate is a highly potent and selective CDK4/6 inhibitor
Data expected by early 2015
Initiation of Phase 1b/2a trial in oncology patients expected in second quarter of...